Merck & Co. reported a 1 percent rise in quarterly revenue, driven by higher sales of its cancer drug, Keytruda. » Read More
Pfizer Chairman and CEO Jeff Kindler last year repeatedly said big deals in big pharma don't work. But, he added, he'd never say never. And sure enough, this year Kindler's buying Wyeth.
This takes the prize for the most dangerously optimistic acronym for a clinical trial. But MADIT (pronounced "made it") made it. Some folks with a lot of chutzpah at Guidant, now owned by Boston Scientific, apparently came up with the name for their big studies on implantable cardio defibrillators.
Wall Street looks ready to transfer funds from bullish to bearish names, the Mad Money host says.
Over the past few months I've blogged a couple of times about the public service announcement Pfizer produced in the UK to discourage guys from buying and taking counterfeit Viagra.
What does it say when a drugmaker hires a Goldman Sachs investment banker as its next Chief Financial Officer? That's the question I'm asking after Novartis announced that it's tapped a managing director of investment banking at Goldman Sachs, Jonathan Symonds, as its CFO apprentice.
Billionaire activist investor (It seems it's become almost de rigueur to put those three words before his name) Carl Icahn is apparently so busy waging a proxy fight against biotechs Amylin Pharmaceuticals and Biogen Idec that he hasn't posted a new blog entry in nearly a month.
This is not a bear market rally but a cyclical bull market, said Barton Biggs, managing partner at Traxis Partners. "We’re about half or 60 percent of the way through the upside.”
Imagine my surprise when I got an email over the weekend from "Diabetic Investor" newsletter editor David Kliff informing me that Amylin Pharmaceuticals is quoting me in a letter to shareholders.
The Glaxo announcement contained the results of the first head-to-head study of GSK’s Cervarix versus Merck’s Gardasil. They’re the shots for the sexually transmitted virus that can cause genital warts and cervical cancer. MRK’s is already on the market. GSK’s has been delayed in getting there.
A new study shows that Merck's Gardasil vaccine protects some young women from a strain of a sexually transmitted disease that can lead to cervical cancer for nearly a decade.
Out of nowhere late yesterday the FDA approved VNDA's schizophrenia drug with the funky name Fanapt.
Against the backdrop of President Obama's healthcare reform effort, the main lobbying group for the generic drug industry says the U.S. healthcare system saved nearly three-quarters of a trillion dollars over the past ten years on generic drugs.
It's a new world. Before Roche bought Genentech, stock-moving drug development milestones for DNA were closely followed by the news media, analysts and investors. But because the Swiss drugmaker Roche only trades over-the-counter in the U.S., the information isn't as "actionable" as it used to be when DNA was around.
You gotta love a good proxy fight, especially when you have one of the kings of shareholder activism, Carl Icahn, in the ring. And lately, I've been getting bombarded by emails from representatives of all corners.
Cramer explains why the market stalled today and what we need to go higher.
Plus, Cramer offers his top pharma pick and highlights the potential for profits in REITs.
Fiesta time started a little earlier than expected for investors in Eli Lilly, Amylin Pharmaceuticals and Alkermes. The companies had said they would file for Food and Drug Administration approval of the once-a-week version of the diabetes drug Byetta in the second quarter, but most analysts thought that meant June.
Whenever a politician, government agency or company puts out news late on a Friday chances are it probably isn't good or it's stuff they'd like to just slip under the door.
Well, it didn't take long. A little more than a month after Roche swallowed Genentech, Dr. Susan Desmond-Hellmann may be headed out the door sooner than anyone thought.
have two reasons to exhale on this TGIF. My month-long stint on the graveyard shift anchoring "Worldwide Exchange" is over and Dendreon is done...for now. After all, Dendreon and its prostate cancer treatment Provenge is the story that just keeps on giving.